Fig. 6: SIRT7 suppresses tumor progression. | Nature Communications

Fig. 6: SIRT7 suppresses tumor progression.

From: Combined intermittent fasting and ERK inhibition enhance the anti-tumor effects of chemotherapy via the GSK3β-SIRT7 axis

Fig. 6

a, b Total tumor number (a), largest tumor (b), and whole tumor weight (c) were analyzed in PyMT;Sirt7+/+ and PyMT;Sirt7+/− mice aged 4 months (n = 5 mice per group); scale bar, 1 cm. d Representative images of H&E staining showing lung metastatic nodules (labeled as T) in PyMT;Sirt7+/+ and PyMT;Sirt7+/− mice, analyzed from n = 5 mice per group; scale bar, 500 µm. e The number of lung metastatic nodules was counted in H&E-stained whole-lung sections (n = 7 mice per group). f–h Tumor burden (f, g) and number (h) in PyMT;WT and PyMT;Sirt7-TG mice (n = 6 per genotype). i, j Representative images showing IHC staining of (pS473)AKT in mammary tumors isolated from PyMT;WT and PyMT;Sirt7-TG mice, analyzed from n = 5 mice per group. Scale bar, 50 µm. Quantification of the relative expression levels of SIRT7 and (pS473)AKT is shown in (j), n = 5 mice per group. k, l Immunoblots (k) and related quantification (l) showing the (pS473)AKT and SIRT7 levels in tumor samples isolated from PyMT;WT and PyMT;Sirt7-TG mice, n = 3 mice per group. Data represent means ± SEM (a, c, e, g, h j, l). P values were calculated by two-tailed Student’s t-test. ***P = 0.0000000003. Source data are provided as a Source Data file.

Back to article page